Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 61 |
| Active Pipeline (Recruiting Now) | 25 (13) |
| Completed vs Stopped Early | 3 / 5 (8.2%) |
| Median Closed Actual Enrollment | 297 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Guangdong Provincial People's Hospital | Guangzhou | 3 |
| Beijing Cancer Hospital | Beijing, Beijing Municipality | 3 |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing | 3 |
Explore interactive annual charts and M&A subsidiary rollups in the Sinocelltech Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.